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Abstract
Background: APOE is the biomarker with the greatest known influence on cognitive function; however, the effect
of complex haplotypes involving polymorphisms rs449647, rs405509, rs440446, rs429358 and rs7412 has never been
studied in older populations.
Methods: We evaluated APOE polymorphisms using multiplex PCR for genotyping and Mini-Mental State Examination
(MMSE) to evaluate cognitive function in 819 individuals from VA Normative Aging Study.
Results: Combinatorial analysis of all polymorphisms and individual analysis of polymorphisms rs449647, rs405509,
rs440446 and rs7412 did not show any association with cognitive performance. Polymorphism rs429358 was associated
with better cognitive performance (odds of MMSE ≤ 25= 0.63, 95% CI 0.42-0.95; p =0.03) in the oldest subsample
(5
th quintile of age) (odds of MMSE≤ 25=0.34; 95%CI 0.13-0.86; p =0.02).APOE allele ε4 was also associated with
better cognitive performance (odds of MMSE≤ 25= 0.61, 95% CI 0.40-0.94; p = 0.02), also in the oldest subsample
(odds of MMSE ≤ 25=0.35, 95%CI 0.14-0.90; p =0.03).
Conclusions: These results suggest a beneficial effect of polymorphism rs429358 in the oldest men.
Keywords: APOE, Epsilon, Alleles, Haplotypes, Cognitive decline, Aging, Genetic variants
Background
As the U.S. population ages, there is growing concern
about the loss of mental acuity that is common through
aging and associated with high financial cost [1], loss of
independence [2] and mortality [3-5]. It has been estimated
that at least 10% of people 65 years or older and 50%
of those≥ 85 years old have some form of cognitive
impairment, ranging from mild deficits to dementia [6].
Biomarkers that predict future risks are critical to design
targeted prevention of cognitive decline. Apolipoprotein E
(APOE) is a protein involved in transport of cholesterol
and lipids throughout the body. It also mediates clearance
of plasma lipoproteins and contributes to redistribution
of lipids to cells [7]. APOE ε4a l l e l e ,d e r i v e df r o mt h e
combination of polymorphisms rs429358 and rs7412, is
the biomarker with the greatest known influence on the
risk of developing Alzheimer’s disease (AD). Nonetheless,
the ε4 allele has been found to be “protective” for AD in
specific age groups, such as younger ages that precede the
bulk of AD diagnosis [8-10] and in population older than
90 years old [11].
In addition to the single nucleotide polymorphisms
(SNPs) used to define the epsilon alleles, two SNPs located
in the promoter region of APOE have been described:
rs449647 and rs405509 [12]. Evidence suggests that this
region modulates transcriptional activity of APOE and that
these polymorphisms may influence its effect on AD
[13,14]. Two studies in populations from Italy have
found an increased frequency of the A/A genotype and
A allele of rs449647 in AD [15,16]. Bizarro et al. [15],
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the G allele in rs405509 in AD than in controls (42.60%
vs. 29.29%), whereas the frequency of the T allele for this
polymorphism was lower in AD than in controls (32.5%
vs. 48.0%) [15]. Polymorphism rs440446, located in intron
1 (enhancer), also affects transcriptional activity of APOE
[18,19]. However, the effect of polymorphisms rs449647,
rs405509, rs440446 and their haplotypes on cognitive
function in older populations has never been studied.
In this study, we evaluated the influence five APOE poly-
morphisms, including the epsilon alleles, in modulating
cognitive function in men between the ages of 49 and
97 years participating in the prospective VA (Veterans
Affairs) Normative Aging Study cohort.
Methods
Study participants
The U.S. Department of Veterans Affairs (VA) Normative
Aging Study (NAS) is an ongoing longitudinal cohort
that was established in 1963, which included men who
were 21–81 years old and free of known chronic medical
conditions at entry [20]. Men have been subsequently
invited to medical examinations every three to five years.
Additionally, participants completed cognitive testing
since 1993. Participants who had experienced a stroke
before the first cognitive test were excluded (3% of indi-
viduals), leaving a total of 819 individuals with cognitive
testing and complete genotyping. The NAS study was
approved by the Institutional Review Boards (IRB) at
participating institutions and all participants provided
written informed consent at each visit.
Genotyping
Genetic polymorphism measurements included rs449647,
rs405509, rs440446, rs429358 and rs7412. Multiplex PCR
assays were designed using Sequenom SpectroDESIGNER
software by inputting sequences containing the single
nucleotide polymorphism (SNP) site and 100 bp flanking
sequence on either side of the SNP. Most assays were
genotyped using the Sequenom MassArray MALDI-
TOF mass spectrometer (SpectroDESIGNER, Sequenom).
Assays that failed to multiplex were genotyped using
TaqMan 5′ exonuclease (Applied Biosystems, Foster City,
CA) and ABI PRISM 7900 Sequence Detector System.
Cognitive test
We administered the Mini-Mental State Examination
(MMSE), a test of global cognition that assesses multiple
cognitive areas, including orientation, immediate and
short-term recall, attention and calculation, word finding,
figure construction, reading and writing skills, and the
ability to follow a 3-step command [21]. MMSE was
designed as a dementia screening tool, but has been
extensively validated and used in epidemiological research.
The range of scores in MMSE is 0 to 30, corresponding to
the lowest and the highest cognitive performance, respect-
ively; however, in this study, the maximum MMSE score
was 29 due to the exclusion of the question on the county
of residence, which has limited meaning in Massachusetts
[21,22]. We included cognitive data from study visits
performed from 1993 through 2004. Although up to 4
cognitive tests were completed by some study partici-
pants, we analyzed only the first cognitive test for each
participant to avoid bias related to better MMSE scores
in repeated tests for each participant due to practice
effect [23]. Also, we note that a large proportion of
participants did not have repeated MMSE measures
over time. Analyses considering cognitive decline are
beyond the scope of this manuscript.
Statistical analysis
Because of the presence of a ceiling effect at the highest
MMSE score (MMSE score=29), which was observed
in 13.06% of our measures, we created a dichotomized
variable for inferior MMSE performance. This approach
has been used previously to provide more robust results
on this dataset [24-26]”. As the MMSE is often used
clinically to screen for dementia, inferior MMSE per-
formance is likely to reflect clinically relevant cognitive
impairment. Only 5.01% of our observations exhibited
scores ≤24, which is the typical screening cut-off score
used in research on dementia. Therefore we considered
scores ≤25 as low performance (22.10% of our observa-
tions), as used in previous studies [27,28]. We evaluated the
main effect of APOE epsilon alleles, complex haplotypes
(observed combinations), and individual polymorphisms
on the odds of having a low MMSE score using logistic
regression with generalized estimating equations (GEE).
All models were adjusted for potential confounders or
predictors of cognitive function assessed at the time of
the MMSE, including age at cognitive assessments (as a
continuous variable), education (<12, 12–16, >16 years),
total cholesterol (continuous), first language (English/not
English), computer experience (yes/no), smoking (current,
former, never), body mass index (BMI) (<25, ≥25 Kg/m
2),
physical activity (<12, 12–30, ≥30 metabolic equivalent
hours (MET-hr) per week), alcohol intake (<2, ≥2 drinks/
day), percentage of the participants that are non-white,
percentage of the participants with at least a college
degree, hypertension (yes/no), dark fish consumption
( < o n c eaw e e k ,≥once a week), and diabetes (yes/no;
d e f i n e da sh a v i n gr e p o r t e dd i a g n o s i so fd i a b e t e so r
having fasting glucose above 126 mg/dl). To determine
the presence of a beneficial effect in the youngest
population, described as the “antagonistic pleiotropyc
effect” and previously reported for APOE ε4 [29], a
similar GEE approach was performed, stratified by
quintiles of age. Additionally, to assess potential interaction
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between age (as a continuous variable) and APOE ε4,
a n di n c l u d e di ti nt h em o d e la l o n gw i t ht h em a i n
effects. Hardy-Weinberg and linkage disequilibrium were
determined using the PROC HAPLOTYPE statement
from SAS software. Finally, all tests were two-sided and
p-values< 0.05 were considered statistically significant.
SAS software (Version 9.3, SAS Institute Inc., Cary,
NC) was used for all statistical analyses.
Results
Characteristics of participants and frequencies
Most of the participants (48.72%) were in the 60–69
years age group, and 34.68% were 70–79 years old. All
of the participants were male and 95% of them were
white. The study sample had 7.33% current smokers and
50.67% reported 12–16 years of education (Table 1). The
minimum value for years of education was 6 years. All
five polymorphisms had minor allelic frequency of at
least 7%, although the frequency of persons who were
homozygous variant ranged from 0.5% to 23% (Table 2).
We constructed a model of all the observed haplotypes
using the three genetic conditions (wild-type, heterozygous,
polymorphic homozygous) for each polymorphism and
we found 54 combinations. The top ten most frequent
haplotypes are shown in Table 3. Based on epsilon alleles
distribution, alleles ε3, ε4a n dε2 showed frequencies of
78.91%, 13.87%, and 6.16%, respectively. Frequencies of
epsilon haplotypes are also shown in Table 3.
Cognitive function according to APOE polymorphisms
and haplotypes
Complex haplotypes (combination of genotypes) exhibited
no association with MMSE≤25 (p>0.05) (Table 4). Also,
analysis of each polymorphism was not associated with
effect on cognitive performance for most of the alleles
(Table 5). Only individuals homozygous for rs429358
minor allele exhibited better cognitive performance rela-
tive to wild type and heterozygous in both unadjusted
(OR=0.63, 95% CI 0.42-0.95 for the odds of MMSE≤25;
p=0.03) and adjusted models (OR=0.62, 95% CI 0.41-
0.95; p=0.03) (Table 5). Multivariable adjusted analysis of
the effect of rs429358 on quintiles of age showed better
cognitive performance only in the oldest population
(5
th quintile of age, Q5) (OR for MMSE ≤ 25=0.34;
95% CI 0.13-0.86; p =0.02) (Figure 1; Additional file 1:
Table S1). Age also modified the association between
rs429358 and cognitive function using the subset Q3-Q5
(OR using unadjusted model=0.89, 95% CI=0.80-0.99,
p =0.03; OR using fully adjusted model=0.90, 95% CI
0.81-1.01; p =0.072) (Additional file 1: Table S2).
Analysis of APOE ε4 allele showed that this allele was
also associated with better cognitive performance (odds of
MMSE ≤25=0.61; 95% CI 0.40-0.94; p=0.02) compared
to non-carriers. Analysis by quintiles of age exhibited a
progressive improvement of cognitive function associated
with APOE ε4 in the population within the highest
Table 1 Demographic characteristics of participants
(n= 819)
Variable n %
Age, years
< 60 92 11.23%
60-69 399 48.72%
70-79 284 34.68%
≥80 44 5.37%
Education
6-12 yrs 245 29.91%
12 to 16 yrs 415 50.67%
> 16 yrs 159 19.41%
Smoking status
Never 245 29.91%
Former 514 62.76%
Current 60 7.33%
Alcohol consumption
Yes 643 78.51%
No 176 21.49%
History of diabetes*
Yes 719 87.79%
No 100 12.21%
Computer experience
Yes 352 42.98%
No 467 57.02%
English as first language
Yes 814 99.39%
No 5 0.61%
Hypertension
Yes 504 61.54%
No 315 38.46%
BMI
>25 640 78.14%
≤25 179 21.86%
Physical activity (MET-hr)
<12 442 53.97%
12-30 217 26.50%
>30 160 19.54%
Dark fish consumption
< once a week 674 82.30%
≥once a week 145 17.70%
*History of diabetes defined as having reported diagnosis of diabetes or
having fasting glucose above 126 mg/dl.
MET-hr: metabolic equivalent hours.
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significantly associated with better cognition only in the
oldest group (Q5) (odds of MMSE≤ 25 in Q5=0.35,
95% CI 0.14-0.90; p =0.03) (Figure 2; Additional file 1:
Table S3). Although all APOE haplotypes were tested,
only ε4 decreased the risk of having low cognitive
scores (Table 6). To determine the role of age in the
association between APOE ε4 and cognitive function in
the oldest group (Q5), we analyzed the effect of age
using the last three quintiles of age (Q3-Q5). Results
exhibited a modest interaction of age on the association
between APOE ε4 and cognitive function in the oldest
population (Q3-Q5) (OR using unadjusted model=0.89,
95% CI=0.81-0.99, p=0.03; OR using fully adjusted
model = 0.90, 95% CI 0.80-1.01; p=0.08) (Additional file 1:
Table S4). Additional analysis of polymorphisms rs449647,
Table 2 Frequencies of genotypes and alleles in APOE
Genotypic frequencies Allelic frequencies
rs449647 WT (AA) 64.47% A 80.59%
HT (AT) 32.23% T 19.41%
Poly (TT) 3.30%
rs405509 WT (AA) 28.08% A 52.63%
HT (AC) 49.08% C 47.37%
Poly (CC) 22.83%
rs440446 WT (GG) 40.78% G 63.13%
HT (GC) 44.69% C 36.87%
Poly (CC) 14.53%
rs429358 WT (TT) 74.4% T 86.20%
HT (TC) 23.7% C 13.80%
Poly (CC) 2.0%
rs7412 WT (CC) 85.59% C 92.55%
HT (CT) 13.92% T 7.45%
Poly (TT) 0.49%
WT= Wild-type; HT = Heterozygous; Poly =Polymorphic.
Table 3 Frequency of APOE haplotypes
Combinatorial n rs449647 rs405509 rs440446 rs429358 rs7412 Frequency
a 125 AA AC GC TT CC 15.26%
b 109 AA AA GG TT CC 13.31%
c 97 AT AC GC TT CC 11.84%
d 68 AA CC CC TT CC 8.30%
e 52 AA AC GG TC CC 6.35%
f 35 AT CC CC TT CC 4.27%
g 31 AA CC GC TC CC 3.79%
h 27 AA AA GG TC CC 3.30%
i 27 AT AA GG TT CT 3.30%
j 21 AA AA GG TT CT 2.56%
Other 227 27.72%
Epsilon
ε3ε29 3 11.36%
ε2ε24 0.49%
ε3ε4 174 21.25%
ε4ε42 0 2.44%
ε4ε11 5 1.83%
ε1ε11 0.12%
ε3ε3 512 62.52%
Table 4 Association between APOE combinatorial
haplotypes and MMSE ≤25 (carriers vs. non-carriers)
Unadjusted
Combinatorial OR (95% CI) p
a 0.913 (0.572 - 1.457) 0.704
b 1.406 (0.890 - 2.221) 0.144
c 1.260 (0.773 - 2.053) 0.354
d 1.410 (0.807 - 2.462) 0.227
e 0.724 (0.346 - 1.514) 0.391
f 1.655 (0.795 - 3.447) 0.178
g 0.511 (0.177 - 1.481) 0.216
h 1.007 (0.400 - 2.534) 0.988
i 1.007 (0.400 - 2.535) 0.988
j 0.364 (0.084 - 1.578) 0.177
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show modification of the risk.
All the polymorphisms analyzed were in Hardy-
Weinberg equilibrium (Additional file 1: Table S5). Link-
age disequilibrium analysis showed dependence between
polymorphisms located at the 3′ APOE coding region,
including the APOE epsilon constituents: rs424358 and
rs7412 (D’=0.70). A strong linkage between other poly-
morphisms was also observed (Additional file 1: Table S6).
Discussion
Our results showed that neither complex haplotypes –
product of the combination of all APOE polymorphisms
evaluated in the present study –, nor the polymorphisms
rs449647, rs405509, rs440446, and rs7412 analyzed indi-
vidually had any association with cognitive function.
However, we found a protective effect of rs429358 on
cognitive function, including a beneficial effect in the
oldest population, as well as an interaction of age with
the same polymorphism in determining cognitive func-
tion. Also, we found a protective effect of the APOE ε4
allele on cognition. Stratified analysis by quintiles of
age also showed that APOE ε4 carriers exhibited better
cognitive performance in the oldest subsample.
APOE is a protein associated with cholesterol-rich and
triglyceride-rich plasma proteins. It is secreted into the
Table 5 Association between APOE polymorphisms and MMSE ≤25
Unadjusted Fully adjusted*
Analysis OR (95% CI) p OR (95% CI) p
rs449647 a 0.431 (0.128 - 1.449) 0.174 0.420 (0.121 - 1.462) 0.424
b 1.190 (0.846 - 1.673) 0.317 1.166 (0.815 - 1.669) 0.401
rs405509 a 1.201 (0.819 - 1.762) 0.349 1.237 (0.824 - 1.857) 0.304
b 0.994 (0.689 - 1.435) 0.975 0.955 (0.649 - 1.406) 0.817
rs440446 a 1.360 (0.873 - 2.120) 0.174 1.305 (0.813 - 2.094) 0.271
b 1.024 (0.732 - 1.434) 0.889 0.997 (0.700 - 1.421) 0.989
rs429358 a 0.498 (0.112 - 2.212) 0.359 0.591 (0.125 - 2.799) 0.507
b 0.634 (0.422 - 0.954) 0.029 0.620 (0.405 - 0.950) 0.028
rs7412 a N/A N/A
b 0.732 (0.442 - 1.211) 0.225 0.697 (0.411 - 1.182) 0.180
N/A: Low number of individuals.
OR= Odds Ratio; 95%CI = 95% Confidence Interval.
*Adjusted for race, education, alcohol consumption, physical activity, diabetes mellitus, fish consumption, computer experience, English as a first language,
cholesterol, smoking, obesity, and hypertension.
Analysis a = (Wildtype + Heterozygous) vs. Polymorphic Homozygous genotypes. Analysis b= Wildtype vs. (Heterozygous + Polymorphic Homozygous) genotypes.
Bold highlights statistical significant result.
Figure 1 Association between rs429358 polymorphism and
MMSE ≤25 by quintiles of age. Adjusted for race, education, alcohol
consumption, physical activity, diabetes mellitus, fish consumption,
computer experience, English as a first language, cholesterol, smoking,
obesity, and hypertension. Results from wild type+heterozygous vs.
polymorphic individuals. Q1-Q5=1
st to 5
th quintile. Numeric values for
Figure 1 are shown in Additional file 1: Table S1.
Figure 2 Association between APOE ε4 status and MMSE ≤25
by quintiles of age. OR=Odds ratio; Variability bars=95% CI.
Adjusted for race, education, alcohol consumption, physical activity,
diabetes mellitus, fish consumption, computer experience, English
as a first language, cholesterol, smoking, obesity, and hypertension.
Results from carriers vs. non-carriers. Q1-Q5= 1
st to 5
th quintile.
Numeric values for Figure 1 are shown in Additional file 1: Table S3.
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lipoproteins (VLDLs), chylomicron remnants, and a sub-
class of high-density proteins. APOE regulates transport
of cholesterol and lipids throughout the body and medi-
ates clearance of plasma lipoproteins [30]. In the central
nervous system, APOE is produced by astrocytes and
circulates incorporated into small particles and disks
resembling high-density lipoproteins. APOE contributes
to redistribution of lipids to cells that require cholesterol
and phospholipids [30].
APOE polymorphisms and haplotypes have been associ-
ated with AD and other human pathological conditions,
but the effects of these combinations on healthy popula-
tions are not completely known. The frequencies of APOE
genotypic and allelic frequencies analyzed here were
similar to those reported in other samples [15,19,31].
Our results did not show associations between cognitive
performance and any of APOE polymorphisms analyzed
here, except for rs429358. This polymorphism exhibited a
beneficial effect on cognitive function which was very
similar to that observed for APOE ε4a l l e l e( w h i c hi s
derived from the combination of polymorphisms rs429358
and rs7412), including its effect in the oldest population
and the interaction of age between the polymorphism and
cognitive function. This finding suggest that APOE ε4
effect could depend of rs429358 only, and is supported
by the strong absence of linkage disequilibrium, a meas-
urement of non-random association between alleles,
between rs429358 and rs7412. Similar linkage disequi-
librium between these two polymorphisms has been
described previously [15]. On the other hand, although
the main effect of the polymorphism could be influenced
by the subset in the first two quintiles of age (Figure 1),
the mediation analysis was statistically significant only
using the oldest populations (Q3-Q5).
Recent work has analyzed cognitive and functional
effects of the APOE ε4 allele. Evans et al. found than
ε4+ individuals perform as well or even better than
ε4- in middle age, possibly due to enhanced-age related
frontal activity and diminished parietal recruitment [32].
T h e s ef u n c t i o n a ld a t ai n d i c a t et h a tAPOE may participate
in compensatory mechanisms at different life stages;
these mechanisms could be activated in older individuals
as a response to impaired activations of brain areas
functionally affected during early ages, and could be ref-
lected in better cognitive performance. Further studies are
warranted to explore cognitive and neural functions in
population of similar age as the NAS cohort.
Interestingly, we are not the first group reporting a
better cognitive function in very old individuals carrying
the APOE ε4 allele. Previous studies have found a reduction
in the impact of the APOE ε4 allele on dementia in extreme
old age, [33] and even a beneficial effect nonagenarians
[11]; therefore, our findings in a subset of our population
(the last quintile of age: mean=77.8; min =74, max=97
years old) could reflect this previously reported effect. Ad-
ditionally, some European studies have suggested that the
effect of the APOE ε4 allele on dementia and mortality dis-
appears in very old age [34]. Also, other studies have found
that the relative prevalence of AD increased from the age of
60 to 89 years old and decreased slightly after age 90 [35].
On the other hand, beneficial effects of APOE ε4a l l e l eh a v e
been reported in other human diseases, including myocar-
dial infarction [36,37].
One of the factors that could influence our results is
the role of sex hormones on the brain and on cognitive
function, as it has been reported previously. AD affects
approximately twice as many women as men and some
studies have suggested that the effect of APOE ε4o n
cognitive function is stronger in women than in men
[8,9,38-42]. We recognize that gender/sex-hormones
could interact in the association between genetic factors
and cognitive performance, and therefore our result is
applicable to men only.
Potential beneficial effects of APOE ε4 on cognition
have been reported in children [41], teenagers [10], young
adults [43], and middle-age adults [9,44]. Based on these
findings, the APOE ε4 allele has been proposed as an ex-
ample of antagonistic pleiotropic effect [45]. Antagonistic
pleiotropy occurs when one gene controls for more than
one trait, where at least one of these traits is beneficial to
the organism’s fitness, and at least one is detrimental to
the organism’s fitness [45]. However, our results did not
show a beneficial effect of APOE ε4 allele in individuals
less than 61 years old (1
st quintile of age, Q1). Previous
additional studies have also failed in demonstrating the
APOE antagonistic pleiotropic effect [46].
We recognize several limitations in our investigation.
Our study is limited by using MMSE as the only score
for cognitive function; therefore these results cannot be
generalized to performance in specific cognitive domains,
which needs to be evaluated in further analyses. Also, our
findings are based on a cohort of older white men and
may apply only to populations with similar characteristics.
Table 6 Association between APOE epsilon alleles and
MMSE ≤25 (carriers vs. non-carriers)
Unadjusted Fully adjusted*
Allele OR (95% CI) p OR (95% CI) p
ε1 0.498 (0.112 - 2.212) 0.359 0.615 (0.131 - 2.893) 0.538
ε2 0.781 (0.455 - 1.342) 0.371 0.784 (0.443 - 1.386) 0.402
ε2 2.043 (0.788 - 5.293) 0.141 2.103 (0.781 - 5.6603) 0.141
ε4 0.639 (0.425 - 0.961) 0.032 0.612 (0.398 - 0.940) 0.024
OR= Odds Ratio; 95%CI = 95% Confidence Interval.
*Adjusted for race, education, alcohol consumption, physical activity, diabetes
mellitus, fish consumption, computer experience, English as a first language,
cholesterol, smoking, obesity, and hypertension. Bold highlights statistical
significant result.
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different populations, including an attenuated effect of
APOE ε4 allele on Hispanics [47]. Tang et al., have also
reported that APOE ε4 allele is a determinant in whites,
but African Americans and Hispanics have an increased
frequency of AD regardless of their APOE genotype [48].
On the other hand, a possible source of bias could be the
inclusion of super-healthy people at the beginning of the
study. Exploratory analysis deleting data from the subset
of population older than 45 during the recruitment did
not affected the results. Also, in this population, we did
not collect data to investigate the role of cognitive reserve.
Cognitive reserve may enhance cognition and modify the
negative effects of pathological changes occurred during
AD, as well as increase cognitive efficiency, capacity, and
flexibility. Although our results were obtained after adjust-
ment by education and computer experience, additional
evaluations of specific domains, including literacy and
vocabulary, may be better suited to reflect the effect of
cognitive reserve [49].
We also recognize that the APOE ε4 allele has been
consistently linked with impaired cognition in older popu-
lations [50-52]. We did not observe any negative effects of
the APOE ε4 allele on cognitive function in our popula-
tion. Several factors might explain this discrepancy, in-
cluding gender, cognitive reserves and differential
functional effect.
Additional studies are warranted to confirm our results
among women and other ethnic groups. Although we
attempted to control for a number of factors involved in
cognitive function (e.g. age, education, computer experi-
ence, etc.), like any other epidemiological study, we cannot
exclude the role of other potential confounders. Although
our results suggest there is no effect of complex APOE
haplotypes on cognitive function, we cannot conclude an
absence of effect on cognition based on the low number
of subjects in each group.
Conclusions
Our study supports the possibility of a beneficial effect of
rs429358 and APOE ε4 allele on cognition in subsets of the
general population, specifically in the oldest men, and sug-
gests that rs429358, and not the combination of other poly-
morphisms, may underlie the effect of the APOE ε4 allele.
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